Newrotex Receives Rapid Regulatory Approval in Panama for First-in-Human Trial of SilkAxons™ Nerve Regeneration Technology
Breakthrough spider silk nerve guide set to transform peripheral nerve repair; clinical trial to launch at The Panama Clinic with bioaccess® as CRO partner
Newrotex Limited has received regulatory approval for its first-in-human clinical trial of SilkAxons™, an advanced bioengineered nerve guide designed to repair severe peripheral nerve injuries. The trial will be conducted at The Panama Clinic in Panama City, with bioaccess®, Latin America’s leading First-in-Human contract research organization (CRO), managing regulatory and clinical operations. This approval—secured just two weeks after ethics board submission—marks a critical milestone in the global development of SilkAxons™, positioning Newrotex at the forefront of next-generation nerve regeneration therapies.
